Impromen Decanoas (Bromperidol)

Bromperidol, the active ingredient in Impromen Decanoas, is a butyrophenone presented as an intramuscular injection for intramuscular use. It is employed to manage schizophrenia and acute psychotic episodes in adult patients. The medication works by antagonizing dopamine D2 receptors, helping to reduce psychotic symptoms and stabilize mood.

GNH USA supplies Impromen Decanoas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality compliance with EU standards and provides reliable global distribution.

Bromperidol is a typical antipsychotic that acts on dopamine pathways to treat serious psychotic disorders.

Schizophrenia: reduces positive and negative symptoms and helps maintain long‑term stability. Acute psychotic episodes: provides rapid control of hallucinations, delusions and agitation. Psychotic agitation: offers fast sedation and symptom relief in severely agitated patients.

Bromperidol may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Sedation or drowsiness - Extrapyramidal symptoms such as tremor or rigidity - Orthostatic hypotension - Dry mouth and increased salivation - Constipation or gastrointestinal discomfort - Weight gain or metabolic changes

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Tardive dyskinesia with prolonged use - Severe hypotension or cardiac arrhythmias - Agranulocytosis or severe leukopenia - Anaphylactic or severe allergic reactions - Elevated prolactin leading to endocrine disturbances

When using Impromen Decanoas, clinicians should observe several safety measures.

Monitor extrapyramidal symptoms: assess for tremor, rigidity, or involuntary movements. Cardiovascular assessment: check blood pressure and heart rhythm before and during therapy. History of neuroleptic malignant syndrome: avoid use in patients with prior NMS episodes. Elderly with dementia: use with caution due to increased risk of cerebrovascular events. Do not discontinue abruptly: taper under medical supervision to prevent withdrawal effects. Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Bromperidol can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Other dopamine antagonists: may increase risk of severe extrapyramidal effects. - CNS depressants (e.g., benzodiazepines, opioids): can enhance sedation and respiratory depression. - QT‑prolonging agents (e.g., certain antiarrhythmics, macrolide antibiotics): raise risk of cardiac arrhythmias. - Monoamine oxidase inhibitors: may cause hypertensive crises.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: bromperidol may potentiate blood‑pressure lowering. - Anticholinergic medications: may mask extrapyramidal symptoms. - CYP450 inhibitors or inducers: can alter bromperidol plasma levels. - Alcohol: may increase sedation and impair coordination.